{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T06:07:01Z","timestamp":1769753221403,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00280-019-03817-2","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T09:10:20Z","timestamp":1553159420000},"page":"1037-1046","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer"],"prefix":"10.1007","volume":"83","author":[{"given":"Makoto","family":"Natsume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-0021","authenticated-orcid":false,"given":"Takaya","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyasu","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kitagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"5","key":"3817_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"1","key":"3817_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, Nishina T, Amagai K, Chin K, Niwa Y, Tsuji A, Imamura H, Tsuda M, Yasui H, Fujii H, Yamaguchi K, Yasui H, Hironaka S, Shimada K, Miwa H, Hamada C, Hyodo I (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141\u2013148. https:\/\/doi.org\/10.1093\/annonc\/mdu472","journal-title":"Ann Oncol"},{"issue":"3","key":"3817_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"issue":"21","key":"3817_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182\u20131186. https:\/\/doi.org\/10.1056\/NEJM197111182852108","journal-title":"N Engl J Med"},{"issue":"6","key":"3817_CR5","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"N Ferrara","year":"2003","unstructured":"Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669\u2013676. https:\/\/doi.org\/10.1038\/nm0603-669","journal-title":"Nat Med"},{"issue":"23","key":"3817_CR6","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335\u20132342. https:\/\/doi.org\/10.1056\/NEJMoa032691 . (350\/23\/2335 [pii])","journal-title":"N Engl J Med"},{"issue":"5","key":"3817_CR7","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2009.23.7537","volume":"28","author":"JL Spratlin","year":"2010","unstructured":"Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O\u2019Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG (2010) Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 28(5):780\u2013787. https:\/\/doi.org\/10.1200\/JCO.2009.23.7537","journal-title":"J Clin Oncol"},{"issue":"9742","key":"3817_CR8","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X","journal-title":"Lancet"},{"issue":"7","key":"3817_CR9","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1200\/JCO.2014.59.4812","volume":"33","author":"E Cutsem Van","year":"2015","unstructured":"Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S, Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 33(7):692\u2013700. https:\/\/doi.org\/10.1200\/JCO.2014.59.4812","journal-title":"J Clin Oncol"},{"issue":"6","key":"3817_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","volume":"18","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18(6):805\u2013835. https:\/\/doi.org\/10.1097\/EDE.0b013e3181577511 . (00001648-200711000-00028 [pii])","journal-title":"Epidemiology"},{"issue":"11","key":"3817_CR11","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, Group RS (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15(11):1224\u20131235. https:\/\/doi.org\/10.1016\/S1470-2045(14)70420-6","journal-title":"Lancet Oncol"},{"issue":"9911","key":"3817_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, Investigators RT (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(13)61719-5","journal-title":"Lancet"},{"issue":"2","key":"3817_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"3","key":"3817_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.tranon.2018.12.006","volume":"12","author":"T Shimura","year":"2019","unstructured":"Shimura T, Iwasaki H, Kitagawa M, Ebi M, Yamada T, Yamada T, Katano T, Nisie H, Okamoto Y, Ozeki K, Mizoshita T, Kataoka H (2019) Urinary cysteine-rich protein 61 and trefoil factor 3 as diagnostic biomarkers for colorectal cancer. Transl Oncol 12(3):539\u2013544. https:\/\/doi.org\/10.1016\/j.tranon.2018.12.006","journal-title":"Transl Oncol"},{"issue":"17","key":"3817_CR15","doi-asserted-by":"publisher","first-page":"29247","DOI":"10.18632\/oncotarget.16453","volume":"8","author":"T Shimura","year":"2017","unstructured":"Shimura T, Ebi M, Yamada T, Yamada T, Katano T, Nojiri Y, Iwasaki H, Nomura S, Hayashi N, Mori Y, Kataoka H, Moses MA, Joh T (2017) Urinary kallikrein 10 predicts the incurability of gastric cancer. Oncotarget 8(17):29247\u201329257. https:\/\/doi.org\/10.18632\/oncotarget.16453","journal-title":"Oncotarget"},{"issue":"3","key":"3817_CR16","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1158\/1940-6207.CAPR-14-0229","volume":"8","author":"T Shimura","year":"2015","unstructured":"Shimura T, Dagher A, Sachdev M, Ebi M, Yamada T, Yamada T, Joh T, Moses MA (2015) Urinary ADAM12 and MMP-9\/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila) 8(3):240\u2013248. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-14-0229","journal-title":"Cancer Prev Res (Phila)"},{"issue":"8","key":"3817_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/bjc.2016.293","volume":"115","author":"CS Fuchs","year":"2016","unstructured":"Fuchs CS, Tabernero J, Tomasek J, Chau I, Melichar B, Safran H, Tehfe MA, Filip D, Topuzov E, Schlittler L, Udrea AA, Campbell W, Brincat S, Emig M, Melemed SA, Hozak RR, Ferry D, Caldwell CW, Ajani JA (2016) Biomarker analyses in REGARD gastric\/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. Br J Cancer 115(8):974\u2013982. https:\/\/doi.org\/10.1038\/bjc.2016.293","journal-title":"Br J Cancer"},{"issue":"3","key":"3817_CR18","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1093\/annonc\/mdx767","volume":"29","author":"J Tabernero","year":"2018","unstructured":"Tabernero J, Hozak RR, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Prausova J, Muro K, Siegel RW, Konrad RJ, Ouyang H, Melemed SA, Ferry D, Nasroulah F, Van Cutsem E (2018) Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. Ann Oncol 29(3):602\u2013609. https:\/\/doi.org\/10.1093\/annonc\/mdx767","journal-title":"Ann Oncol"},{"issue":"23","key":"3817_CR19","doi-asserted-by":"publisher","first-page":"6614","DOI":"10.1158\/1078-0432.CCR-13-1442","volume":"19","author":"AX Zhu","year":"2013","unstructured":"Zhu AX, Finn RS, Mulcahy M, Gurtler J, Sun W, Schwartz JD, Dalal RP, Joshi A, Hozak RR, Xu Y, Ancukiewicz M, Jain RK, Nugent FW, Duda DG, Stuart K (2013) A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 19(23):6614\u20136623. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-1442","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3817_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ygyno.2014.06.029","volume":"134","author":"RT Penson","year":"2014","unstructured":"Penson RT, Moore KM, Fleming GF, Braly P, Schimp V, Nguyen H, Matulonis UA, Banerjee S, Haluska P, Gore M, Bodurka DC, Hozak RR, Joshi A, Xu Y, Schwartz JD, McGuire WP (2014) A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol 134(3):478\u2013485. https:\/\/doi.org\/10.1016\/j.ygyno.2014.06.029","journal-title":"Gynecol Oncol"},{"issue":"43","key":"3817_CR21","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","volume":"269","author":"J Waltenberger","year":"1994","unstructured":"Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988\u201326995","journal-title":"J Biol Chem"},{"issue":"3","key":"3817_CR22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/sj.onc.1201545","volume":"16","author":"E Landgren","year":"1998","unstructured":"Landgren E, Schiller P, Cao Y, Claesson-Welsh L (1998) Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1. Oncogene 16(3):359\u2013367. https:\/\/doi.org\/10.1038\/sj.onc.1201545","journal-title":"Oncogene"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03817-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03817-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T03:26:22Z","timestamp":1663125982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03817-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3817"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03817-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"19 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}